Characterization of circulating myeloma tumor cells by next generation flowcytometry in scleromyxedema patient: a case report

Rubia Y. Taha, MD8, Saba Hasan, MSc, PhD8, Firyal Ibrahim, MD3, Yannick Chantran, D.Pharmc, Hesham El Sabah, MDa, Siveen Sivaraman, MSc, PhD3, Issam Al Bozom, MD3, Ahmad Al Sabbagh, MD8, Laurent Garderet, MD8, Halima El Omri, MDe, Halima El Omri, MDa, Hesham El Sabah, MDa, Siveen Sivaraman, MSc, PhDd, Issam Al Bozom, MDb, Ahmad Al Sabbagh, MDb, Saba Hasan, MSc, PhDa, Firyal Ibrahim, MDb, Yannick Chantran, D.Pharmc, Halima El Omri, MDe

Abstract

Introduction: Scleromyxedema (rare cutaneous mucinosis), is characterized by the formation of lichenoid papules and presence of serum monoclonal IgG in most cases, or all; after repeated testing.

Patient concerns: The patient is a 51-year-old male presented with thick, disfiguring elephant-like erythematous skin folds over the forehead, papular shiny eruptions over ears and trunk and waxy erythematous papules over arms and hands without dysphagia or respiratory or neurologic symptoms.

Diagnosis: Skin biopsy from right arm was consistent with scleromyxedema. Serum cryoglobulin was reported negative. Complete blood count and routine blood biochemistry were normal. Thyroid function tests were normal. Protein electrophoresis and immunofixation showed monoclonal band of 14.5 g/L typed as IgG lambda.

Interventions: Our patient was refractory to lenalidomide however improved clinically on immunoglobulins infusions on monthly basis without change in the MGUS level.

Outcomes: NGF analysis revealed approximately 0.25% Lambda monotypic plasma cells in the bone marrow expressing CD38, CD138, and CD27 with aberrant expression of CD56 and were negative for CD45, CD19, CD117, and CD81. We also detected 0.002% circulating plasma cells (PCs) in peripheral blood.

Conclusion: The immunophenotype of circulating tumor cells (CTCs) remain close to the malignant PCs phenotype in the BM. Hence, we report NGF approach as a novel diagnostic tool for highly sensitive MRD detection in plasma cell dyscrasias including scleromyxedema.

Abbreviations: ALP = alkaline phosphatase, ASQPCR = Allele-Specific Oligonucleotide Quantitative Polymerase Chain Reaction, BM = bone marrow, CR = complete response, CTC = circulating tumor cells, CTPC = circulating tumor plasma cells, FACS = fluorescence-activated cell sorting, FCY = Flow Cytometry, FITC = Fluorescein isothiocyanate, HMC = Hamad Medical Corporation, IF = immunofixation, IRB = Institutional Review board, LOD = Limit of Detection, MGUS = Monoclonal Gammapathy Of Undetermined Significance, MM = multiple myeloma, MRD = Minimal Residual Disease, MRI = Magnetic Resonance Imaging, NGF = next generation flow cytometry, NGS = next generation sequencing, NPPR = The National Priorities Research Program, OS = overall survival, PB = peripheral blood, PBS BSA = phosphate buffered saline bovine serum albumin, PBS-Tween = phosphate buffered saline with tween, PC = plasma cell, PCR = polymerase chain reaction, PUVA = psoralen and ultraviolet A, QNRF = Qatar National Research Fund, SM = scleromyxedema, SPEP = serum protein electrophoresis.

Keywords: biomarkers, immune response, immunoblotting, immunophenotyping, minimal residual disease, next generation flowcytometry, scleromyxedema

Editor: Maya Saranathan.

This research was supported by QNRF NPRP Grant # 7-916-3-237. We thank our colleagues from National Center for Cancer Care Research (NCCCR), Hamad Medical Corporation, Doha, Qatar and Dr Garderet Laurent, Department of Hematology & Immunology, Hospital, St Antoine, Paris, France who provided insight and expertise that greatly assisted the research.

The authors have no funding and conflicts of interests to disclose.

The authors report no conflicts of interest.

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

How to cite this article: Taha RY, Hasan S, Ibrahim F, Chantran Y, Sabah HE, Sivaraman S, Bozom IA, Sabbagh AA, Garderet L, Omri HE. Characterization of circulating myeloma tumor cells by next generation flowcytometry in Scleromyxedema patient: a case report. Medicine 2020;99:27(e20726).

Received: 27 November 2019 / Received in final form: 2 April 2020 / Accepted: 11 May 2020
http://dx.doi.org/10.1097/MD.0000000000020726
1. Introduction

Treatment outcomes of multiple myeloma (MM) have progressed so much that have led to the implementation of new response criteria, including minimal residual disease (MRD) status as one of the most essential clinical endpoints. Currently, the landscape for multiple myeloma treatment has modified substantially, leading to increased complete response (CR) rates and survival. Still, most CR patients ultimately show relapse. Therefore, highly sensitive methods are needed for detection of minimal residual disease (MRD). Conventional 4–8-color flow cytometry (FCM), is the technique of choice for monitoring MRD in bone marrow (BM) of MM after therapy. Multiparameter flow cytometry’s immunophenotyping is an anchor for monitoring of most hematologic malignancies. It has high relevance in differential diagnostic workup because of its steady and conclusive readout of plasma cell (PC) clonality and delivering of prognostic information in monoclonal gammopathies. The main function of FCM is measurement of intrinsic optical properties of particles, such as size or cytoplasmic complexity of a single blood or bone marrow cells, also the presence of intracytoplasmic or membrane protein within such a cell, by previous binding with a fluorochrome-coupled specific antibody.

FCM is being a routine qualitative and quantitative technique, commonly used in standard clinical testing as well as in different scientific areas. In general, FCM is based on the analysis of light scattering characteristics of a cell suspension (size and granularity). The additional specific characteristics of the biological sample are obtained via the fluorescent probes used in the experiment (Fig. 1). The use of different fluorophores allows experimenters and researchers to analyze multiple parameters in a single assay. In hematology, FCM is a sensitive technique crucial for medical diagnosis and disease management. It allows different applications like DNA content analysis, immunophenotyping, and assessment of structural and functional properties of biological samples. Multi-color flow cytometry for MRD measurements in multiple myeloma can be considered applicable in all MM patients (95%) as compared to allele-specific oligonucleotide quantitative polymerase chain reaction (ASOqPCR) and next generation sequencing (NGS) (50%–90% cases). The superiority of applicability in flow-MRD is mainly due to the high level of primer annealing variability and the unpredictable amplification/quantitation results in NGS. On the other hand, PCR and NGS have higher sensitivity ($10^{-9}$–$10^{-4}$) compared to conventional flow-MRD ($10^{-4}$). More recently, the limit of detection (LOD) was improved in next generation flow-MRD ($10^{-5}$ and $10^{-4}$), making it as sensitive as PCR-based MRD methods at the condition of enough cell number should be measured. Next generation flow cytometry (NGF) is recently considered as a robust sensitive tool to evaluate monoclonal gammopathy of undetermined significance (MGUS) and MM.

Scleromyxedema (SM) is a chronic, progressive, and potentially fatal mucinosis of the skin, displaying increased collagen and fibroblast proliferation with irregular distribution, along with involvement of various internal organs. Pathogenesis of this fatal mucinosis remains unclear. The high prevalence of monoclonal gammopathy (MGUS) in up to 80% of patients is an indication of a possible B-cell immune response to antigenic mucin deposits in the dermis. It was described by Rongioletti and Rebora (2001) as a generalized papular and sclerodermoid eruption, associated with monoclonal gammopathy (mostly IgG-λ paraproteinemia) and a triad of histological features: presence of mucin deposition within the upper and mid reticular dermis, fibroblast proliferation and fibrosis with the absence of a thyroid disorder. Histopathological analysis highlights a number of mucin deposits in papules and sclerotic malformations, comprising of thickened collagen fibers, due to which, lichenoid papules are formed which cause thickening and hardening of the tissue. Diagnosis depends on 4 criteria:

1. Papular cutaneous eruption in a sclerodema-like distribution;
2. Skin biopsy showing triad of dermal mucin deposition, proliferation of fibroblasts, and fibrosis;
3. Monoclonal gammopathy;
4. Absence of thyroid dysfunction.

The etiology of SM remains unknown. However, the pathogenesis of the disease has been suspected to be linked to the monoclonal. FCM is part of the initial diagnostic work-up, after assessment of patients clinical history and results of morphological assessment of blood and bone marrow, mainly because of its capacity to provide conclusive results within a specified period.

In the current study, we described the phenotypic characterization of clonal plasma cells in a patient with SM where the BM and the circulating plasma cells are examined. Additionally, the purpose of this article is to provide an overview of the methodology of NGF and to highlight some applications of this technique in clinical practice, specifically, as a tool for Scleromyxedema. The patient has provided informed consent for publication of the case.

2. Methods

The study was conducted with the approval of Hamad Medical Corporation (HMC) Institutional Review board (IRB) with a signed consent from the patient. Ethical approval was obtained from HMC-IRB (Study No: 14-226/14; JIRB No: 14-00089; QRNF No: NPRP7-916-3-237) for the research proposal entitled: Standardization of phenotypic and molecular techniques for characterization of circulating plasma cells and minimal residual diseases cells: understanding disease dissemination and chemoresistance, and approved on December 20, 2016.
Immunoblotting experiments were performed as follows: serum protein electrophoresis was performed in agarose gel (0.8%, pH 8.6) using a Sebia HYDRASIS, according to the manufacturer recommendations. After the migration and before the drying phase, the gel was taken out of the device and proteins were blotted on a nitrocellulose membrane during 10 minutes under a weight of 20 g/cm². The membrane was then saturated during 1 hour with nonfat dry milk 5% H₂O. After 3 washing steps with PBS-Tween 0.05%, membrane strips were incubated 1 hour with primary monoclonal antibodies (HP6053, HP6054, NL16, GOM2, ZG4, RJ4, TM15, HP6018, G7C, X3A8, HP6017. See Table 1 for specificity) diluted in PBS BSA 2%. After 3 washing steps with PBS-Tween 0.05%, membrane strips were incubated 1 hour with secondary polyclonal anti-mouse IgG antibody coupled to the Alkaline Phosphatase (ALP), diluted in PBS BSA 2%. After washing steps, the presence of ALP was revealed by NitroBlue Tetrazolium / 5-bromo-4-chloro-3-indolyphosphate system.

FCM was performed by next generation multiparametric flow cytometry utilizing BD Fortessa and analyzing the data using Infinicyt software (Cytognos SL). Both peripheral blood and bone marrow were evaluated by Bulk lyse-Stain-Wash protocol using a direct 8-color immunofluorescence combination; CD38 FITC, CD56 PE, CD45 PerCP-cy5.5, CD19 PE-Cy7, CD117 APC, CD81 APC-Cy7, CD138 Pacific Blue, CD27 BV510 for characterization of the immunophenotypic protein expression profile and a combination of CD38 FITC, CD56 PE, CD45 PerCP-Cyanine 5.5, CD19 PE-Cyanine 7, Kappa APC, Lambda APC-Cy7, CD138 - BV421, CD27 BV510 for characterization of cell clonality.

3. Results
We applied the NGF technique in the clinical setting of a case of scleromyxedema having MGUS as part of his presentation.

3.1. Case description
We describe a 51-year-old male with history of thick, disfiguring elephant like erythematous skin folds over the forehead, papular shiny eruptions over ears and trunk and waxy erythematous papules over arms and hands. No systemic manifestation, dysphagia or respiratory or neurologic symptoms were reported. On admission, sclerodermoid lesions, pseudosclerodermaous thickening of the exposed skin and thickening on the trunk and extremities were seen in the patient (Fig. 2A and 2B). Skin biopsy showed deposition of mucinous material compatible with scleromyxedema (Fig. 3A and 3B).

The laboratory investigations (Table 2) revealed mild normocytic normochromic anemia; hemoglobin 11.8 g/dl with normal white cell counts and platelet counts. Blood morphology showed increased rouleaux formation. Kidney, liver, thyroid

| Table 1 | Monoclonal antibodies used for immunoblotting. |
|---------|-----------------------------------------------|
| S.No. | Antibody clone # | Isotype/domain specificity |
| 1. | HP6053 | Kappa, constant domain |
| 2. | HP6054 | Lambda, constant domain |
| 3. | NL16 | IgG1, CH2 domain |
| 4. | GOM2 | IgG2, CH3 domain |
| 5. | ZG4 | IgG3, hinge region |
| 6. | RJ4 | IgG, CH3 domain |
| 7. | TM15 | IgG, CH1 domain |
| 8. | HP6018 | IgG, CH2 domain |
| 9. | G7C | IgG, CH2 domain |
| 10. | X3A8 | IgG, CH3 domain |
| 11. | HP6017 | IgG, CH3 domain |

Figure 2. Patient disfiguring elephant like erythematous skin. (A) Erythematous thick skin folds over forehead. (B) Waxy and firm erythematous papules over ear.
functions were normal, calcium level was normal. Serum protein electrophoresis (SPEP) and immunofixation (IF) showed monoclonal band 14.5 gm/l typed as IgG lambda. Urine Bence Jones protein was negative for monoclonal protein. Beta2 microglobulin and lactate dehydrogenase were normal. Serum cryoglobulines were negative.

Radiologic investigations included ultrasound abdomen showed normal findings. Total body magnetic resonance imaging (MRI) did not reveal any focal osseous lesion. Echocardiography revealed normal parameters. All investigations excluded myeloma and could be explained by MGUS in the setting of scleromyxedema.

### Table 2

| Investigation                | Result              | Reference range |
|-----------------------------|---------------------|-----------------|
| WBC                         | 4.70 x 10^3 /μL     | [4–10.00]       |
| Hb                          | 17.8 g/dl           | [13–17]         |
| Platelets                   | 150 x 10^3 /μL      | [150–400]       |
| Urea                        | 6.20 mmol/L         | [2.76–8.07]     |
| Creatinine                  | 88 μmol/L           | [70–115]        |
| Calcium                     | 2.26 mmol/L         | [2.10–2.60]     |
| Total protein               | 85 g/dl             | [66–87]         |
| Albumin                     | 45 g/dl             | [35–50]         |
| Alkaline phosphatase        | 36 UL               | [40–129]        |
| Bilirubin total             | 13.6 μmol/L         | [0–21]          |
| ALT                         | 13 UL               | [0–40]          |
| AST                         | 16 UL               | [0–37]          |
| LDH                         | 163 UL              | [135–225]       |
| Beta 2 microglobulin        | 2.46 mg/L           | [0.97–2.64]     |
| SPEP and IF                 | IgG Lambda 14.5 g/L |                 |
| Kappa/lambda ratio          | 0.69                 | [0.26–1.650]    |
| Free light chain kappa      | 15.53 mg/L          | [3.30–19.40]    |
| Free light chain lambda     | 22.28 mg/L          | [5.71–26.30]    |
| Ferritin                    | 279 μg/L            | [24–336]        |
| Vitamin B12                 | 200 pmol/L          | [133–675]       |
| FT4                         | 19.5 pmol/L         | [11.6–21.9]     |
| TSH                         | 2.6 mIU/L           | [0.30–4.20]     |
| Glucose                     | 5 mmol/L            | [3.3–5.5]       |
| Serum Cryoglobulin          | Negative            |                 |

3.2. Immunoblot study rational

A monoclonal immunoglobulin present in SM has been described decades ago by Kitamura et al (1979)\(^{25}\) as an IgG lambda with deletion of the heavy chain constant domain CH1. We performed immunoblotting experiments in order to investigate potential CH deletion in the patients monoclonal immunoglobulin. The first immunoblotting experiment with anti-IgG subclasses anti-sera showed a reactive band at the same migration as the monoclonal band on total protein electrophoresis with anti-Lambda, anti-IgG, and anti-IgG1 antibodies, but not with anti-Kappa, anti-IgG2, -IgG3, or -IgG4. We conclude that the monoclonal immunoglobulin belongs to the IgG1 subclass (Fig. 4A). The second immunoblotting experiment showed consistent immuno-reactivity of the monoclonal band with monoclonal antibodies directed against IgG CH1, CH2, and CH3 domains (Fig. 4B). We exclude the complete deletion of a CH domain within this monoclonal immunoglobulin and conclude that partial deletion of a CH domain is unlikely.

Bone marrow aspirate smear revealed active trilineage haemopoiesis with approximately 4% plasma cells, mostly mature, with occasional plasmablastic and binucleated forms. Bone marrow biopsy was cellular with adequate haemopoietic cells. Immunohistochemistry with CD138, Kappa and Lambda revealed increased plasma cell comprising approximately 6% to 9% of bone marrow cellularity as, scattered, clusters, and aggregates, with Lambda restricted (Fig. 5).

Immunophenotyping analysis by NGF revealed approximately 0.25% Lambda monotypic plasma cells in the bone marrow expressing CD38, CD138, CD27 with aberrant expression of CD56 and were negative for CD45, CD19, CD117, and CD91. In the peripheral blood 0.002% circulating Lambda monotypic plasma cells were detected with similar immunophenotype expression (Figs. 6 and 7).

As evident from studies of Juan Flores et al (2016),\(^{26}\) myeloma PCs display phenotypes that deviate from those typically seen in normal PCs, including normal BM PCs. Markers that have been associated with informative aberrant antigen expression profiles for MRD monitoring in MM include: CD19, CD56, CD45, CD38, CD27, and to a less extent also CD20, CD28, CD33, CD117, and Smlg. On the other hand, the combination of these markers (or a subset of
Figure 4. Gel electrophoresis showing identification of Immunoglobulin sub classes (A): first experiment was dedicated to the identification of Ig subclasses and light chain type. (B): second experiment was performed with antibodies specific for the 3 constant domains of the heavy chain.

Figure 5. Bone marrow biopsy (H&E) 40×: cellular core biopsy. Immunohistochemistry on core biopsy (100×): CD138 immunostaining: positive, increased plasma cells scattered and in clusters. Kappa immunostaining: Rare positive cells, Lambda immunostaining: Many positive cells.
them) with cytoplasmic immunoglobulin (CyIg) lambda (L) and kappa (K) light chain staining may also contribute to establish the clonal nature of a population of suspicious PCs. Currently, additional markers are identified as aberrantly expressed by MM PCs in variable percentages of patients. Among these latter markers, CD81, CD200, CD54, and CD307 have emerged as most informative ones.

The patient was treated with lenalidomide 25 mg daily; The M band responded. However, skin lesions were refractory and progressing, the patient discontinued the drug after 1 year because of repeated infections and lack of efficacy. Subsequently the patient started second line treatment with IV immunoglobulin 2 g/kg divided over 3 days, he achieved favorable cutaneous response in spite of persistent paraproteinemina.

---

**Figure 6.** Bone Marrow next generation Flow cytometer: 0.25% plasma cells; Clonality: Lambda. Immunophenotype: A: CD45+, B: CD38++, C: CD138++, D: CD19+, E: CD56 Heterogeneous, F: CD27+, G: CD117-, H: CD81-.

**Figure 7.** Peripheral Blood next generation Flow cytometer: 0.002% plasma cells; Clonality: Lambda. Immunophenotype: A: CD45+, B: CD38++, C: CD138 Heterogeneous, D: CD19-, E: CD56 Heterogeneous, F: CD27+, G: CD117-, H: CD81-.
4. Discussion

Scleromyxedema is a rare chronic disorder that may affect middle-aged adults (30 to 80 years old) at equal prevalence for both genders without any ethnic predominance.[27,28] The etiology of the disease is still unclear. However, there are 4 diagnostic criteria commonly reported in SM patients

1. cutaneous mucinosis involving flesh-colored waxy rash with firm papules and sclerodermoid often in a linear array
2. microscopic triad (deposition of mucin, fibroblast proliferation)
3. monoclonal gammopathy, and absence of thyroid disease.[28–30] Moreover, the disease has been reported to be associated with neurologic symptoms.[31]

Histologically, both scleromyxedema and lichen myxoedematous show fibroblast proliferation and mucin (acid mucopolysaccharides) deposition in the superficial dermis between the collagen bundles with marked thickening of the dermis in case of scleromyxedema. In order to differentiate between these entities, thyroid dysfunction must be excluded and a monoclonal gammopathy shown in peripheral blood.[32] The underlying mechanism and causes of scleromyxedema remain a challenge. However, the description about diagnostic criteria and treatment plan has increased the awareness and early recognition of the disease in recent years.[33] Hence, there is no clarity in explanation of mucin deposition origin, paraprotein role and the next pulls for the IF which leads to a diluted sample when affecting the low burden of disease in the BM. The BM aspiration is a method that can be utilized for MRD. Current MRD assays are being routine clinical practices in patients diagnosed with different malignancies.[42] There is a consistent association between MRD negativity by FCM and improved progression-free and overall survival.[43,44] However, MRD assays are lacking standardization with reported variability in FCM-MRD methodology and sensitivity.[44] Currently, various markers and antibody panels, distinct numbers of cells measured, and MRD positivity criteria are applied worldwide.[45,46] Hence, standardization efforts as well as consensus recommendations have been proposed recently.[45–47] These consensus recommendations still rely on subjective “expert-shared” knowledge and experience, and do not offer complete solution for the lack of technical standardization.[44]

Several publications, streaming over the past decade have emerged, demonstrating enhanced prediction of outcome using flow MRD testing for MM over conventional response assessments.[10–13,48–50] In these studies, FCM has been shown to be an independent predictor of progression free survival (PFS) and overall survival (OS). Multiparametric flow cytometry is a high potential technique that facilitates analysis of a large number of events in heterogeneous cellular specimens, thereby providing information on a cell-by-cell basis, with an ability to acquire high number of cells rapidly. Thus, flow cytometry is well suited for rare event detection in assays such as FCM MRD.

Standard therapy for systemic treatment of scleromyxedema has not been established yet. Numerous medications and methods are used with varying therapeutic effects.[39] These include: topical application and intralesional injection of hyaluronidases, systemic administration of corticosteroids, radiotherapy, psoralen, and ultraviolet A (PUVA) phototherapy, plasmapheresis combined with pulsed corticosteroids and/or immunosuppressive therapy, intravenous immunoglobulin combined with thalidomide, extracorporeal photochemotherapy,[5,51–54] retinoid,[55] peripheral blood autologous stem cell transplantation.[52] Our patient was refractory to lenalidomide however improved clinically on immunoglobulins infusions on monthly basis without change in the MGUS level. This case shows the impact of NGF in the upfront diagnosis of MGUS in SM and because of high sensitivity can be largely utilized in the follow up after therapy.

Author contributions

Conceptualization: Ruba Y. Taha, Laurent Garderet, Halima El Omri.

Data curation: Ruba Y. Taha, Saba Hasan, Yannick Chantran, Siveen Sivaraman.

Formal analysis: Ruba Y. Taha, Firyal Ibrahim.

Funding acquisition: Ruba Y. Taha, Halima El Omri.

Investigation: Zhi-bin Tian, Saba Hasan, Yannick Chantran, Siveen Sivaraman.

Methodology: Ruba Y. Taha, Yannick Chantran, Ahmad Al Sabbagh.

Project administration: Ruba Y. Taha, Saba Hasan, Firyal Ibrahim, Yannick Chantran, Hesham El Sabah, Siveen Sivaraman, Issam Al Bozom, Ahmad Al Sabbagh, Laurent Garderet, Halima El Omri.

Resources: Saba Hasan, Firyal Ibrahim, Yannick Chantran, Siveen Sivaraman, Issam Al Bozom.

Software: Saba Hasan, Firyal Ibrahim, Yannick Chantran, Siveen Sivaraman, Issam Al Bozom.

Supervision: Ruba Y. Taha, Saba Hasan, Firyal Ibrahim, Yannick Chantran, Hesham El Sabah, Siveen Sivaraman, Issam Al Bozom, Ahmad Al Sabbagh, Laurent Garderet, Halima El Omri.

Validation: Ruba Y. Taha, Saba Hasan, Firyal Ibrahim, Yannick Chantran, Hesham El Sabah, Siveen Sivaraman, Issam Al Bozom, Ahmad Al Sabbagh, Laurent Garderet, Halima El Omri.
**Visualization:** Ruba Y. Taha, Saba Hasan, Firyal Ibrahim, Yannick Chantran, Hesham El Sabah, Sivene Sivaraman, Issam Al Bozom, Ahmad Al Sabbagh, Laurent Garderet, Halima El Omri.

**Writing – original draft:** Ruba Y. Taha, Saba Hasan, Yannick Chantran, Hesham El Sabah.

**Writing – review & editing:** Ruba Y. Taha, Laurent Garderet, Halima El Omri.

---

**References**

[1] Landgren O, Iskander K. Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. J Intern Med 2017;281:363–82.

[2] Lahuerta JJ, Mateos MV, Martinez-Lopez J, et al. Influence of pre- and post-transplantation responses on outcome of multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008;26:5773–82.

[3] Sonneveld P, Goldschmidt H, Rosinol L, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 2013;31:3279–87.

[4] Usmani SZ, Crowley J, Hoering A, et al. Improvement in long-term outcomes with successive total therapy trials for multiple myeloma: are patients now being cured? Leukemia 2013;27:226–32.

[5] Palumbo A, Bringenh S, Larocca A, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol 2014;32:634–40.

[6] Mateos MV, Leleu X, Palumbo A, et al. Initial treatment of transplantineligible patients in multiple myeloma. Expert Rev Hematol 2014;7:67–77.

[7] Rolig C, Knop S, Bornhauser M. Multiple myeloma. Lancet 2015;385:2197–208.

[8] Mateos MV, Ocio EM, Paiva B, et al. Treatment for patients with newly diagnosed multiple myeloma in 2015. Blood Rev 2015;29:387–403.

[9] Paiva B, Gutierrez NC, Rosinol L, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict sustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012;119:687–91.

[10] Paiva B, Martinez-Lopez J, Vidriasles MB, et al. Comparison of immunofluorescence, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol 2011;29:1627–33.

[11] Paiva B, Montalban MA, Puig N, et al. Clinical significance of sensitive Flow-MRD monitoring in elderly multiple myeloma patients on the Pethema/GEM2010MA65 Trial. Blood 2014;124:3390.

[12] Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 2013;31:2540–7.

[13] Rawstron AC, Davies FE, DasGupta R, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002;100:3905–100.

[14] Rawstron AC, Gregory WM, de Tute RM, et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit by log reduction. Blood 2013;125:1932–5.

[15] Robillard N, Rene MC, Moreau P, et al. A single tube multiparameter sevencolour flow cytometry strategy for the detection of malignant plasma cells in multiple myeloma. Blood Cancer J 2013;3:e134.

[16] Brown M, Wittwer C. Flow cytometry: principles and clinical applications in hematology. Clin Chem 2008;44:8 Pt 2:1221–9. Review.

[17] Flores-Montero J, Sanoja-Lores I, Paiva B, et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 2017;31:2094–103.

[18] Theunissen P, Mestrikova E, Sedek L, et al. EuroFlow Consortium-Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood 2017;129:347–57.

---

**Recent Trends in Myeloma Research**

[19] Sanoja-Flores I, Flores-Montero J, García JJ, et al. EuroFlow consortium Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J 2018;8:117.

[20] Sanee S, Davarnia G. Scleromyxedema without paraproteinemia: treatment with thalidomide and prednisolone. Case Rep Dermatol 2016;8:327–32.

[21] Ronigoletti F, Rebaro A. Updated classification of popular mucinous, lichen myxematous and scleromyxedema. J Am Acad Dermatol 2001;44:273–81.

[22] Serdar ZA, Yasar SP, Erfan GT, et al. Generalized popular sclerodermoid eruption: scleromyxedema. Indian J Dermatol Venereol Leprol 2010; 76:592–602.

[23] Binitha MP, Nanadkumar G, Thomas D. Suspected cardiac toxicity to intravenous immunoglobulin used for treatment of scleromyxedema. Indian J Dermatol Venereol Leprol 2008;74:248–50.

[24] Mehta V, Balachandrana C, Raghavendra R. Arndt Gottron Scleromyxedema: successful response to treatment with steroid minipulse and methothrexate. Indian J Dermatol 2009;54:193–5.

[25] Kitamura Y, Shimada M, Go S. Presence of mast cell precursors in fetal liver of mice. Dev Biol 1979;70:510–4.

[26] Flores-Montero J, de Tute R, Paiva B, et al. Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom 2016;96:61–72.

[27] Ronigoletti F, Merlo G, Cinotti E, et al. Scleromyxedema: a multi-center study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol 2013;69:66.

[28] Caudill L, Howell E. Scleromyxedema: a case clinically and histologically responsive to intravenous immunoglobulin. J Clin Aesthetic Dermatol 2014;7:45–7.

[29] Bologna J, Torizzo JL, Rapini R, Schaffer JV. Dermatology. 2nd edn. 2008:611–614.

[30] Rey JB, Luzia RB. Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin. J Am Acad Dermatol 2009;60:1037–41.

[31] Fett NM, Toporcer MB, Dalmau J, et al. Scleromyxedema and dermatoneuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib. Am J Hematol 2011;86:891–6.

[32] Van Leersum F, Abdul Hamid M, Steijlen P. Scleromyxedema. Lancet 2017;389:1549.

[33] Koronowska SK, Osmola-Marlickowa A, Jakubowicz O, et al. Scleromyxedema: a rare disorder and its treatment difficulties. Postepy Dermatol Alergol 2013;30:122–6.

[34] Atzori L, Ferrehi C, Ronigoletti F. Advances in understanding and treatment of scleromyxedema. Expert Opin Orphan Drugs 2018;6:319–28.

[35] Oh SJ, Oh SH, Jun YJ, et al. Paraneoplastic atypical scleromyxedema with advanced gastric cancer. JAAD Case Rep 2017;3:376–8.

[36] Aoki M, Matsushita S, Kawai K, et al. Scleromyxedema clinically resembling to scleroderma. Indian J Dermatol 2016;61:127.

[37] Gimenez Garcia R, Garcia SG, Suarez Vilela D, et al. Scleromyxedema syndrome with intravenous immunoglobulin. J Am Acad Dermatol 2009;60:1037–41.

[38] Helm F, Helm TN. Iatrogenic myelomonocytic leukemia following melphalan treatment of scleromyxedema. Cuta-scale 1987;39:219–23.

[39] Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:549–9.

[40] Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:549–9.

[41] Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:549–9.

[42] Paiva B, Paimo T, Sayagues JM, et al. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood 2013;122:3591–8.

[43] Bae MH, Park CJ, Kim BH, et al. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma. Cytometry B Clin Cytom 2018;94:493–9.

[44] van Dongen JF, van der Velden VH, Bruggemann M, et al. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood 2015;125:3996–4009.
[44] Flanders A, Stetler-Stevenson M, Landgren O. Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. Blood 2013;122:1088–9.

[45] Salem D, Stetler-Stevenson M, Yuan C, et al. Myeloma minimal residual disease testing in the United States: evidence of improved standardization. Am J Hematol 2016;91:E502–3.

[46] Stetler-Stevenson M, Paiva B, Stoolman L, et al. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Cytometry B Clin Cytom 2016;90:26–30.

[47] Rawstron AC, Orfao A, Beksc M, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008;93:431–8.

[48] Arroz M, Came N, Lin P, et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom 2016;90:31–9.

[49] Paiva B, Vidrales M-B, Cervero J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008;112:4017–23.

[50] San Miguel JF, Almeida J, Mateo G, et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood 2002;99:1853–6.

[51] Weening RH, Pittelkow MR, Wolff K, Goldsmith L, Katz S, Gilchrest B, Leff ell D, Paller A. Scleredema and Scleromyxedema. Fitzpatrick’s Dermatology in General Medicine 7th edn New York: Mc Graw Hill Medical; 2008;1562–1566.

[52] Laimer M, Namberger K, Massone C, et al. Vincristine, idarubicin, dexamethasone and thalidomide in scleromyxoedema. Acta Derm Venereol 2009;89:631–5.

[53] Efthimiou P, Blanco M. Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxoedema: case report and discussion of the literature. Semin Arthritis Rheum 2008;38:188–94.

[54] Meigel W, Burgdorf WH, Plewig G, Wolf HH, Landthaler M. Mucinoses. Braun-Fakö’s Dermatology 3rd edn Munich: Springer; 2009;1263-1273.